Clinical effect of neoadjuvant chemotherapy combined tumor cells to destroy the loss in treatment of patients with advanced ovarian cancer
10.3760/cma.j.issn.1008-6315.2015.11.025
- VernacularTitle:新辅助化疗联合肿瘤细胞减灭术治疗晚期卵巢癌的效果分析
- Author:
Enling LIU
;
Yuxiu ZHOU
;
Ruoran MI
;
Dehua WANG
;
Liqun WANG
;
Yanmei ZHANG
- Publication Type:Journal Article
- Keywords:
Ovarian cancer;
Tumor remove;
Neoadjuvant chemotherapy;
Clinical effect
- From:
Clinical Medicine of China
2015;31(11):1041-1043
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the clinical effect of neoadjuvant chemotherapy combined tumor cells to destroy the loss in treatment of patients with advanced ovarian cancer.Methods One hundred and forty-four patients with advanced ovarian cancer were divided randomly into the control group(n=72) and research group (n=72).The patients of control group were given conventional chemotherapy(ovarian tumor remove first and then neoadjuvant chemotherapy) and the patients of research group were given neoadjuvant chemotherapy (neoadjuvant chemotherapy first and then ovarian tumor remove).The operation time, intraoperative blood loss, hospital stay, ideal reduction rate, clinical efficacy and postoperative complications between the two groups were compared.Results The operation time, intraoperative blood loss, hospital stay of the research group were obviously lower than that of the control group((124.6±21.3) min vs.(186.4±32.6) min, (382.5±62.3) ml vs.(618.5± 86.4) ml, (8.9± 1.3) d vs.(12.2± 3.4) d;t =5.623,9.646,5.257), while the ideal reduction rate of the research group were obviously higher than that of the control group(70.8％ vs.47.2％, x2 =8.735), the differences were statistically significant(P＜0.05).The clinical efficacy(87.5％ vs.52.8％, x2 =6.748) of the research group were obviously higher than that of the control group, while the postoperative incision infection (9.7％ vs.19.4％, x2 =4.452) and fever(4.2％ vs.15.3％,x2 =5.536) were obviously lower than that of the control group, the differences were statistically significant (P＜0.05).Conclusion The treatment of neoadjuvant chemotherapy can obviously increase the the clinical effect of treatment of patients with advanced ovarian cancer and decrease the postoperative complications, it is worth popularization and application.
